The Science of GLP-1

How GLP-1 Works

GLP-1 (Glucagon-Like Peptide-1) is a natural incretin hormone released by the gut after meals. It travels through the body and binds to specific proteins called GLP-1 receptors, which act like cellular switches. These receptors are found in key organs such as the pancreas, brain, liver, heart, bones, and fat tissue.

What HUMMSA offers

Hummsa’s lead molecule, HB PK002, is a next-generation, small-molecule GLP-1 receptor agonist. It mimics natural GLP-1 to activate the same therapeutic pathways, but with greater precision and accessibility.

Why Preventive GLP-1
Agonists?

GLP-1 therapies have reshaped diabetes and obesity care, but most only manage symptoms.

At Hummsa, we focus on prevention and regeneration. Our molecule, HB PK002, is built for ease of use—and to slow, halt, or even reverse disease before lasting damage occurs.

When GLP-1 receptors are activated, they trigger a cascade of beneficial responses:

Pancreas releases more insulin to lower blood sugar

Liver cuts down glucose
production

Brain reduces appetite and supports cognition

Digestion slows and inflammation eases

Project HB PK002 Overview

HB PK002 is a first-in-class oral small-molecule GLP-1 receptor agonist currently in preclinical development. Unlike peptide injectables, it stimulates repair and regeneration of insulin-producing beta cells in the pancreas which get damaged in diabetes.

HB PK002 activates GLP-1 receptors in metabolic tissues, modulating key pathways related to

Lipid Metabolism

Glucose Regulation

Neural Protection

Inflammation

Bone Health

Breaking past the limits of current therapies

Insulin producing beta cell regeneration
Improved insulin sensitivity
Oral administration
No cold-chain storage
Scalable manufacturing

Development Pipeline

Hummsa’s pipeline is advancing rapidly through preclinical development, preparing for Investigational New Drug (IND) enabling studies. Our lead molecule, HB PK002, targets six key indications, all leveraging GLP-1 receptor activation tailored to specific disease biology.

HUB PK002_T1D
HUB PK002_T2D
HUB PK002_OB
HUB PK002_Liver
HUB PK002_OP
HUB PK002_AD
Target:
Pancreas
Indication:
T1D
Discovery
Pre Clinical
Phase 1
Phase 2
Phase 3
Target:
Pancreas
Indication:
T2D
Discovery
Pre Clinical
Phase 1
Phase 2
Phase 3
Target:
Body
Indication:
Obesity
Discovery
Pre Clinical
Phase 1
Phase 2
Phase 3
Target:
Liver
Indication:
MASLD / MASH
Discovery
Pre Clinical
Phase 1
Phase 2
Phase 3
Target:
Skeletel
Indication:
Osteoporosis
Discovery
Pre Clinical
Phase 1
Phase 2
Phase 3
Target:
Cortex
Indication:
AD
Discovery
Pre Clinical
Phase 1
Phase 2
Phase 3